Blincyto (Blinatumomab)

Block 1

Blincyto (Blinatumomab) Wholesaler

Blincyto (Blinatumomab) wholesaler, supplier 


Blincyto (Blinatumomab) is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. 

In March 29, 2018 U.S. Food and Drug Administration (FDA) approved  Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). MRD refers to the presence of cancer cells below a level that can be seen under the microscope. In patients who have achieved remission after initial treatment for this type of ALL, the presence of MRD means they have an increased risk of relapse. 


  • Blincyto (blinatumomab) 35 mcg/vial  wholesaler

Rasso Swiss Pharma is Blincyto (blinatumomab) wholesaler, distributor and supplier.

<< Back to products